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by targeting the gp41 prehairpin fusion
intermediate induced by CD4 D1D2 domains
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Background: Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and
fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly
inactivate virions away from cells. Although soluble CD4 (sCD4) can inactivate laboratory-adapted HIV-1 strains,
it fails to reduce the viral loads in clinical trials because of its low potency against primary isolates and tendency
to enhance HIV-1 infection at low concentration. Thus, it is essential to design a better HIV inactivator with
improved potency for developing new anti-HIV therapeutics that can actively attack the virus in the circulation
before it attaches to and enter into the target cell.
Results: We engineered a bivalent HIV-1 inactivator, designated 2DLT, by linking the D1D2 domain of CD4 to
T1144, the next generation HIV fusion inhibitor, with a 35-mer linker. The D1D2 domain in this soluble 2DLT protein
could bind to the CD4-binding site and induce the formation of the gp41 prehairpin fusion-intermediate (PFI),
but showed no sCD4-mediated enhancement of HIV-1 infection. The T1144 domain in 2DLT then bound to the
exposed PFI, resulting in rapid inactivation of HIV-1 virions in the absence of the target cell. Beside, 2DLT could
also inhibit fusion of the virus with the target cell if the virion escapes the first attack of 2DLT.
Conclusion: This bivalent molecule can serve as a dual barrier against HIV infection by first inactivating HIV-1
virions away from cells and then blocking HIV-1 entry on the target cell surface, indicating its potential for
development as a new class of anti-HIV drug.
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Thus far, thirty-two anti-HIV drugs (including five
fixed-dose combinations) have been licensed by the
United States Food and Drug Administration (FDA) for
treatment of HIV infection/AIDS (http://www.hivandhe-
patitis.com/hiv_and_aids/hiv_treat.html). Most of these
drugs act inside the host cell to inhibit viral replication by
targeting HIV reverse transcriptase, protease, or integrase.
Two of them, enfuvirtide (also known as T20) [1] and
Marviroc [2], act on surface of the target cell to block* Correspondence: shibojiang@fudan.edu.cn
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reproduction in any medium, provided the orviral fusion and entry by interacting with the HIV-1 gp41
N-terminal heptad repeat (NHR) and the coreceptor,
CCR5, respectively. However, none of these anti-HIV drugs
can inactivate virions in the absence of the target cell.
Some of the non-ionic surfactants, such as Nonoxynol-
9 (N-9), could effectively inactivate HIV-1 virions by
lysing the viral envelope membrane [3]. However,
because of its high cytotoxicity, it cannot be used as an
anti-HIV drug in clinics since it can also damage cellular
membranes [4]. Therefore, it is essential to design an
HIV inactivator using a protein or peptide that can
actively attack the virion before it attaches to and enters
into the host cells, with low or no toxic effect on the
host cells.
To infect a target cell, HIV-1 first binds to the cellular
receptor CD4 and then a co-receptor, CXCR4 or CCR5
through its envelope glycoprotein (Env) surface subunitThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subunit gp41 changes its conformation from native to
prehairpin fusion intermediate (PFI) state by inserting
the fusion peptide (FP) into the target cell membrane.
Three molecules of the gp41 N-terminal heptad repeats
(NHR) interact with each other to form a N-trimer, a
PFI conformation, which is then associated with the
gp41 C-terminal heptad repeats (CHR) to form a
hairpin-like six-helix bundle (6-HB) (Figure 1A), bring-
ing the viral and cellular membranes into close proxim-
ity necessary for fusion [5-7]. Mutations in the multiple
highly conserved tyrosine and dileucine motifs in gp41
cytoplasmic domain lead to a loss of HIV-1 Env-
mediated membrane fusion [8], and several specific
amino acid changes in gp120 V3 region and gp41 are
associated together with CXCR4 and/or CCR5 usage [9],
suggesting that both gp120 and gp41 play important
roles in HIV-1 entry and are attractive targets for devel-
oping an HIV-1 inactivator and/or entry inhibitors [10].
Monomeric soluble CD4 (sCD4) that can specifically
binds to the HIV-1 gp120 and then inactivate the virion
was one of the first anti-HIV-1 agents tested in clinical
trial. Unfortunately, it failed to reduce the viral loads in
HIV-1-infected individuals [12,13]. However, sCD4 and
CD4-mimetics could efficiently induce the formation of
the gp41 PFI with the exposed grooves on the NHR-
trimer [14], which is the target of peptidic HIV fusion
inhibitors, such as SJ-2176 [15], T20 [16], C34 [17,18]
and T1144 [19,20]. These results suggest that a molecule
containing a CD4 or CD4-mimetic and a gp41 PFI-
binding domain (such as T1144) can inactivate HIV-1
more efficiently than sCD4 or CD4-mimetic since T1144
can bind to the exposed gp41 grooves induced by bind-
ing of sCD4 or CD4-mimetic to gp120 to speed the virus
inactivation. Based on this hypothesis, we engineered a
bivalent protein, designated 2DLT, in which the D1D2
domains of CD4 were linked to T1144 by a 35-mer flex-
ible linker to allow the free movement of the two func-
tional domains in the bivalent molecule (Figure 1B). The
D1D2 fragment in this bivalent protein is expected to
bind specifically with gp120 on the surface of HIV vir-
ions or HIV-infected cells (Figure 1C) and trigger forma-
tion of the gp41 PFI with the exposed hydrophobic
grooves (Figure 1D), while the T1144 domain can bind
to the exposed grooves on the gp41 NHR-trimer, result-
ing in rapid inactivation of the cell-free HIV-1 before its
attachment to the target cell. Indeed, the 2DLT protein
could effectively bind to both gp120 and gp41, block
gp41 6-HB formation, inactivate cell-free HIV-1 and in-
hibit HIV-1 Env-mediated cell-cell fusion, but without
the sCD4-mediated enhancing effects on HIV-1 infec-
tion. Therefore, this engineered bivalent molecule has
substantial potential for development as an anti-HIV
therapeutic for treatment of patients who fail to respondto the current anti-HIV drugs and as a topical microbi-
cide for preventing sexual transmission of HIV.
Results
Construction, expression and characterization of the
bivalent fusion protein 2DLT
The expression plasmids pD1D2-PDI and p2DLT-PDI
were constructed by linking the DNA fragment encoding
D1D2 with those coding the 35-mer linker (GGGGS)7
and T1144 sequentially by three-step overlapping PCR
using the corresponding primer pairs. The nucleotide
sequences of the vectors were confirmed by DNA se-
quencing. The recombinant bivalent protein 2DLT and
the control protein D1D2 (Figure 1B) were expressed in
E. coli. To avoid the formation of inclusion bodies, we
used the protein disulfide isomerase (PDI) chaperone-
expression system since we and others have shown that
PDI, as a fusion partner, could significantly increase the
soluble expression of recombinant proteins in the cyto-
plasm of E. coli [21,22], and we successfully obtained
soluble D1D2 and 2DLT proteins. After purification, we
analyzed these proteins with SDS-PAGE and Western
blot. On the gels, two proteins migrated near the
expected position of the proteins (Figure 1Ea, D1D2:
~23KD; 2DLT: ~29KD). Both displayed specific inter-
action with anti-CD4 polyclonal antibodies (pAb)
(Figure 1Eb). While the anti-T1144 pAb bound with
2DLT at the predicted size, no band was revealed in
the D1D2 lane (Figure 1Ec). Similarly, anti-CD4 pAb
(T4-4) could react with both D1D2 and 2DLT, while
anti-T1144 pAb was able to recognize 2DLT only in the
ELISA. Notably, both D1D2 and 2DLT could react with
the CD4-specific and conformation-dependent mono-
clonal antibody (mAb) Sim.4 (Figure 1F), suggesting
that the soluble D1D2 and 2DLT may have a correctly
folded conformation.
2DLT inactivated cell-free HIV-1 virions
To determine whether 2DLT could inactivate HIV-1
virions, we used PEG-6000 method, as previously
described [23-26], to separate HIV-1 from the recombin-
ant proteins 2DLT and D1D2, as well as the control pep-
tides T1144 and T20, and then measured the residual
infectivity of the treated HIV-1 particles. As shown in
Figure 2 and Table 1, 2DLT inactivated cell-free HIV-1
Bal (laboratory-adapted R5 virus), HIV-1 IIIB (labora-
tory-adapted X4 virus), and primary R5 isolates with dif-
ferent subtypes (92US657, 93 MW959, and 92TH009) in
a dose-dependent manner with 50% effective concentra-
tion (EC50) ranging from 17.3 to 78.6 nM, which is
about 2- to 6-fold more potent than D1D2 against the
corresponding viral strains. In contrast, T20 and T1144
at a concentration up to 500 nM did not show signifi-
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Figure 1 Design, expression and characterization of 2DLT. A) The schematic view of the interactions between the NHR and CHR of gp41
and C-peptides. The dashed lines between NHR and CHR indicate the interaction between the residues located at the e and g positions in
the NHR and the a and d positions in the CHR. The sequences of peptide T20, C34 and T1144 are shown, and the pocket-forming sequence
(aa 565–581) in the NHR and pocket-binding domain (aa 628–635) in the CHR are colored in red and green, respectively. B) Schematic view of
the 2DLT and D1D2 molecules (not drawn to scale). The D1D2 of CD4 (aa 1–185) and T1144 are connected by a 35-mer of linker (GGGGS)7.
C) A diagram showing the predicted structure of 2DLT interacting with gp120. The complex containing the gp120 core (yellow), the two-domain
sCD4 (D1D2) (red) and the T1144 (green), was derived from the coordinates of the published X-ray crystallographic complex [11] using the Pymol
program (http://pymol.sourceforge.net). D) The model of CD4-induced gp41 PFI. Soluble CD4 (sCD4) or CD4 D1D2 domains bind to HIV-1 Env
surface subunit gp120, resulting in the formation of the gp41 PFI with the exposed grooves on the NHR-trimer, which is a target for HIV-1
inactivator. E) Characterization of 2DLT. The soluble recombinant proteins 2DLT and D1D2 were expressed in E. coli using the PDI-chaperone
expression system and analyzed by SDS-PAGE (a); Western blot using anti-CD4 polyclonal antibody (b); anti-T1144 polyclonal antibody (c); and
by ELISA using anti-CD4 pAb T4-4, a conformation-dependent mAb Sim.4 and anti-T1144 pAbs F). The data are representative of results from
three similar experiments performed in triplicate (means ± SD).





































































































Figure 2 Inactivation of HIV-1 by 2DLT. Recombinant proteins
and peptides were added to HIV-1 Bal (A), HIV-1 IIIB (B), and
92US657 (C), respectively, followed by incubation for 60 minutes at
4°C. The mixtures were then cooled on ice before addition of PEG-
6000 solution at a final concentration of 3% for separation of HIV-1
particles as described in the Methods. The HIV-1 particles containing
pellets were re-suspended in tissue culture medium and titered for
infectivity. The percentage of residual infectivity is shown in a scale.
The data are representative of results from three similar experiments
performed in triplicate (means ± SD).





D1D2 2DLT T1144 T20
Bal (B, R5) 157.2 ± 34.2 24.5 ± 2.25 >500 >500
IIIB (B, X4) 51.2 ± 9.21 17.3 ± 1.62 >250 >250
92US657 (B, R5) 319.2 ± 56.1 48.7 ± 14.5 >500 >500
93 MW959 (C, R5) 478.2 ± 89.3 78.6 ± 7.04 >500 >500
92TH009 (E/A, R5) 209.5 ± 6.1 69.9 ± 14.4 >500 >500
* Data are representative of two similar experiments tested in triplicate
(mean ± SD).
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the bivalent protein 2DLT is capable of directly inactivat-
ing HIV-1, making it a good potential candidate for
developing novel anti-HIV drugs.Like sCD4 and D1D2, 2DLT could bind to gp120 on the
cell surface
To investigate the inactivation mechanism of 2DLT, we
first determined whether the bivalent protein 2DLT
retains the biological activities of CD4. As expected,
2DLT could bind to gp120 protein as strongly as sCD4
and D1D2, while T1144 was unable to bind with gp120
as shown in ELISA (Figure 3A). We then used SPR
assays to determine whether the 35-mer linker L35 and
the C-peptide T1144 in the bivalent protein would affect
the binding affinity of the D1D2 domain in 2DLT to
gp120. The results confirmed that 2DLT could interact
with gp120 in a dose-dependent manner with high bind-
ing affinity (KD = 1.9e-8) comparable to D1D2 (KD =
2.1e-8), while T1144 exhibited no binding to gp120
(Figure 3B). Using a flow cytometry assay, we demon-
strated that 2DLT could bind to the native gp120/gp41
(Env) expressed on the surfaces of CHO-WT cells as ef-
fectively as sCD4 and D1D2, while T1144 was unable to
bind to the cell-expressed Env without sCD4 stimula-
tion. None of these peptides or proteins could bind to
CHO-EE cells that express no Env of HIV-1 (Figure 3C).Like T1144, 2DLT bound to the groove on the gp41 PFI
N-trimer and subsequently blocked gp41 6-HB formation
To determine whether 2DLT, like T1144, could interact
with the exposed grooves on the gp41 N-trimer, we
tested the binding activity of 2DLT to 5-helix, a mimic
of N-trimer with exposed groove, using an ELISA.
As shown in Figure 4A, 2DLT could bind to 5-helix
as effectively as T1144, while D1D2 and sCD4 exhibited
no significant binding, suggesting that the soluble
recombinant protein 2DLT can function like T1144 to
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Figure 3 Binding of the soluble 2DLT and D1D2 proteins to gp120 protein or to gp120 expressed on the cell surface. A) Binding of
sCD4, D1D2, 2DLT, T1144 to rgp120 as measured by ELISA. The data are representative of results from three similar experiments performed
in triplicate (means ± SD). B) The binding affinity of sCD4 (a), D1D2 (b), 2DLT (c), and T1144 (d) to gp120 as determined by SPR assay.
The recombinant gp120 (rgp120) was immobilized onto the CM3 sensor chip. The proteins and peptide at various concentrations were
injected onto the surface. The affinity constant of each sample was calculated in one-site binding modes by BIAcore evaluation software.
C) Binding of sCD4, D1D2, 2DLT, and T1144 to the HIV-1 Env (gp120/gp41) expressed on CHO-WT cell surfaces as determined by flow cytometry.
CHO-EE cells expressing no HIV-1 Env molecule were used as control cells.
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Figure 4 Inhibition of gp41 6-HB formation by 2DLT. A) Binding of D1D2, 2DLT, and T1144 to the grooves on the 5-helix as assessed by
ELISA. B) The inhibition of D1D2, 2DLT, and T1144 to the 6-HB formation between N36 and C34-biotin was detected by ELISA. Each sample was
tested in triplicate, and the data are presented as means ± SD. C) The inhibition of D1D2 and 2DLT at graded concentration to the 6-HB
formation between N36 and C34-FAM was determined by FN-PAGE. The peptide N36 was incubated with 2DLT or D1D2 at 37°C for 30 minutes
before addition of the peptide C34-FAM at graded concentrations. After incubation for another 30 minutes, the mixtures were analyzed by
FN-PAGE (panels a and b). The gels in panels a and b were stained with Coomassie Blue (panels c and d).
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http://www.retrovirology.com/content/9/1/104The gp41 6-HB formation is a critical step during
HIV-1 fusion with the target cell. The peptides derived
from the gp41 CHR, e.g. C34 and T1144 are able to bind
with viral gp41 N-trimer to block the 6-HB core forma-
tion [19,27]. Here, we used a sandwich ELISA and fluor-
escence native polyacrylamide gel electrophoresis (FN-
PAGE) to determine if 2DLT, like T1144, possessed in-
hibitory activity on gp41 6-HB formation in a model sys-
tem mimicking the gp41 6-HB core formation by mixing
the gp41 N36 and C34 (or FAM-labeled C34) peptides
at equal molar concentration [17,28]. In the ELISA,
2DLT, like T1144, inhibited the 6-HB formation in a
dose-dependent manner with an IC50 of 0.5 ±0.06 μM,
while D1D2 protein at 10 μM exhibited no significantinhibition (Figure 4B). Similarly, 2DLT could effectively
block 6-HB formation in a dose-dependent manner
when it was tested at 5, 10, and 20 μM as shown in the
FN-PAGE (Figure 4Ca and Cc, lanes 5 to 7), whereas
D1D2 protein at the same concentrations showed
no significant inhibition (Figure 4Cb and Cd, lines 5 to
7). The D1D2 and 2DLT bands were not observable
on the gels because they carry net positive charges,
like the N-peptide N36 (lane 1 in Figure 4C) and run
in a reversed direction under the native gel condition
as previously described [27,29]. These results indicate
that 2DLT can interact with the gp41 N-trimer and block
the 6-HB core formation between viral gp41 NHR and
CHR domains.
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http://www.retrovirology.com/content/9/1/1042DLT could disrupt the function of the CD4-induced gp41
PFI, and caused no significant enhancement of HIV-1
infection in CD4-/CCR5+ cells
Recently, Haim et al. have demonstrated that binding of
sCD4 or CD4-mimetics to HIV-1 gp120 could induce a
short-lived PFI N-trimer, resulting in increased bindingInterval between the proteins pulse and addition of C34-biotin at 25 OC ( min )
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Figure 5 2DLT-mediated rapid decay of the CD4-induced gp41
PFI and lack of D1D2-induced enhancement of HIV-1 infection
in CD4-/CCR5+ cells. A) Decay of the gp41 PFI at 25°C (a) and 4°C
(b) after pulse activation with D1D2 (2.5 μM), 2DLT (2.5 μM) or
T1144 (2.5 μM) was measured by a cell-based ELISA, as described in
the Methods. B) The infectivity of HIV-1 Bal (100 TCID50/well) in
Cf2Th-CCR5 (CD4-/CCR5+) cells in the presence of D1D2, 2DLT or
T1144 was determined by ELISA for p24 antigen production as
described in the Materials and Methods.of the C34-Ig protein to the groove on the N-trimer,
using a cell-based ELISA as described in Methods. Using
a similar approach, we examined whether 2DLT may act
on this intermediate to rapidly inactive viruses by the
interaction of T1144 domain on it and NHR of gp41 on
Env. Indeed, binding of C34 to HIV-1 Env was rapidly
enhanced after D1D2 pulse, and then gradually
decreased as the time of D1D2 pulse was prolonged at
25°C (Figure 5Aa) or 4°C (Figure 5Ab), which are coinci-
dent with the report by Haim et al. There was no C34
binding immediately after T1144 pulse. Strikingly, the
binding ability of C34 to the pulsed Env was lost more
rapidly in the 2DLT group than the D1D2 group at 25°C
(Figure 5Aa) and 4°C (Figure 5Ab). These results suggest
that because of the presence of T1144 in the bivalent
molecule, 2DLT can decay the N-trimer-exposed PFI at
a faster rate than D1D2. Therefore, we believe that
2DLT may have a mechanism of action different from
D1D2 molecule in inactivating the CD4-induced gp41
PFI. The D1D2 domain in 2DLT may destabilize the
gp41 PFI triggered by its binding to gp120, while its
T1144 domain may interact with the exposed N-trimer
in the viral gp41 to form heterogonous 6-HB, resulting
in the stabilization of the gp41 PFI. It has been reported
that sCD4 can modestly enhance the infectivity of some
HIV-1 strains at suboptimal concentrations in CD4-
CCR5+ cells because sCD4 may efficiently replace CD4
on cell surface to drive infection of the CD4-negative and
CCR5-positive cells [30]. Here, we investigated whether
2DLT could enhance infectivity of CCR5-using HIV-1
strain Bal in Cf2Th-CCR5 (CD4-/CCR5+) cells, using
D1D2 and T1144 as controls. As shown in Figure 5B,
D1D2 at the concentrations from 5 to 200 nM signifi-
cantly enhanced the infection of the virus in the CD4-/
CCR5+ cells, while 2DLT and T1144 at the same concen-
trations showed no enhancement of HIV-1 infection, sug-
gesting that 2DLT exhibits no enhancing effect on HIV-1
infectivity in CD4-/CCR5+ cells.
2DLT inhibited HIV-1 infection and HIV-1-mediated cell-
cell fusion
Subsequently, we determined the inhibitory activities of
2DLT against HIV-1 IIIB-mediated cell-cell fusion and
against infection by laboratory-adapted HIV-1 IIIB
(X4) and Bal (R5) strains in MT-2 and TZM-b1 cells, re-
spectively, as well as several primary HIV-1 isolates in
PBMCs using D1D2, T1144 and T20 as controls. Like
T1144 and T20, 2DLT also exhibited potent inhibitory
activities against HIV-1 IIIB-mediated cell-cell fusion
(IC50 = 19.03 nM) and infection by HIV-1 strains IIIB
(IC50 = 5.64 nM) and Bal (IC50 = 10.78 nM), which are
about 5- to 15-fold more potent than D1D2 (Figure 6).
Similarly, 2DLT could also significantly inhibit infection
by the primary HIV-1 isolates tested at a low nanomolar
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Figure 6 Inhibition of 2DLT on HIV-1 infection. The infectivity of
IIIB (subtype B, X4) in MT-2 cells (A) or HIV-1 Bal (subtype B, R5) in
TZM-bl cells (B) in the presence or absence of the fusion protein
(D1D2 or 2DLT) or peptide (T20 or T1144) was detected by using
in-house p24 kits or Promega’s luciferase kits, respectively.
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anti-HIV-1 activity than D1D2 in all assays. These
results suggest that 2DLT, in addition to its HIV-1 in-
activation function, can also serve as an HIV-1 fusion/
entry inhibitor, like T20, against a broad spectrum of
HIV-1 strains, irrespective of co-receptor usage.
To determine the effect of preincubation of the virus
with an inhibitor on the inhibitor’s anti-HIV-1 activity,
we preincubated HIV-1 Bal virus with 2DLT, D1D2,
T1144 or T20 for 0, 15, 60 and 240 minutes, respect-
ively, before addition of the mixture to TZM-bl cells.
Their inhibitory activity on HIV-1 Bal infection was then
tested. We found that the potency of 2DLT remarkably
increases with increasing preincubation times. After pre-
incubation for 240 minutes, the inhibitory activity of
2DLT was increased about 4-fold, while that of T1144,
D1D2 and T20 was increased only about 0.3- to 0.6-fold
(Table 3). This result suggests that preincubation of2DLT with HIV-1 may trigger the increased exposure of
the gp41 PFI, because of the increased binding of D1D2
domain in 2DLT with gp120 on virions, resulting in the
increased binding of its T1144 domain to the exposed
gp41 PFI and enhanced inhibition of HIV-1 infection.Discussion
Soluble CD4 (sCD4) was previously recognized as a po-
tential HIV-1 inactivator since it can bind to gp120 for
inducing inactivation of HIV-1 virions. However, a very
high concentration of sCD4 is required to neutralize
infection by primary HIV-1 isolates [14,31,32]. Even
worse, sCD4 at low concentration can enhance HIV-1
infection of CD4-/CCR5+ cells [14]. To improve sCD4-
mediated HIV-1 neutralizing activity, several groups
have constructed hybrid proteins by fusing CD4 or
D1D2 with human IgG (CD4-IgG2 or PRO 542) [33,34]
or with a monoclonal antibody (mAb) specific for the
CD4-induced epitope, such as 17b (sCD4-17b) [35]. In a
clinical trial, CD4-IgG2 treatment led to about 0.5 log10
reduction in viral load [34]. However, CD4-IgG fusion
proteins have two limitations. First, the molecule is too
large to be expressed in a large quantity. Second, the
inactivator targeting only gp120 may not be very effect-
ive in rapid decay of the gp41 PFI, a critical step of in-
activating HIV-1 [14]. Therefore, the CD4-induced gp41
PFI is expected to be a novel target for development of
HIV inactivators with improved efficacy.
In this study, we engineered a bivalent HIV-1 inactiva-
tor, 2DLT by targeting CD4-induced gp41 PFI with
exposed grooves on the NHR-trimer. It consists of a
D1D2 fragment of CD4, a 35-mer linker, and a C-
peptide T1144 (Figure 1B). As expected, 2DLT could
effectively inactivate HIV-1, including both laboratory-
adapted and primary strains with different subtypes and
tropism (Figure 2 and Table 1). It bound to gp120 via its
D1D2 domain (Figure 3A-C) and then interacted with
the exposed grooves on the NHR-trimer via its T1144
domain, resulting in a rapid decay of the gp41 PFI
(Figure 5A). Unlike sCD4 and D1D2, 2DLT did not en-
hance HIV-1 infection in CD4-/CCR5+ cells (Figure 5B).
Like T1144, 2DLT could also bind to the exposed groove
on the gp41 NHR-trimer (Figure 4A) and inhibit the
gp41 6-HB core formation (Figure 4B and C), as well as
block HIV-1 fusion and replication through its T1144
domain (Figure 6 and Table 2). The bivalent HIV-1
inactivator 2DLT is able permanently to inactivate HIV-
1 at any time it comes into contact with the virions,
while T20 can only inhibit HIV-1 fusion within several
minutes when the virion or virus-infected cell attaches
to the target cell (Figure 7). Compared with the non-
ionic surfactant-based virus inactivators, such as N9
[36,37] and C31G [38,39], 2DLT protein has much lower
Table 2 Inhibitory activity of the recombinant proteins and peptides on HIV-1-mediated cell-cell fusion and HIV-1
replication
Concentration (nM) D1D2 2DLT T20 T1144
IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
HIV-1 IIIB-mediated cell fusion
97.83 137.18 19.03 46.51 20.15 41.71 5.89 15.26
HIV-1 replication
IIIB (B, X4) 56.80 246.02 5.64 28.79 17.26 117.21 2.13 35.23
Bal (B, R5) 170.20 >250 10.78 44.35 43.35 >250 4.03 28.11
92US657 (B, R5)* >250 >250 17.17 51.85 56.07 223.92 13.21 42.26
93 MW959 (C, R5)* >250 >250 18.93 48.86 4.70 18.76 2.35 16.25
92TH009 (E/A, R5)* 25.30 113.69 17.50 71.93 1.43 7.99 1.36 6.21
*Primary HIV-1 isolates.
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centration) value greater than 100 μM on the cells sus-
ceptible to HIV-1 infection and reproductive tract
epithelial cells (data not shown), and better specificity
since it specifically interacts with the HIV-1 Env, rather
than other components that are also present in host cells
[40,41]. Compared with sCD4 or D1D2, 2DLT can decay
the CD4-induced gp41 PFI much more rapidly and effi-
ciently through the interaction of its T1144 domain with
the exposed grooves on the NHR-trimer.
Similar to several gp120-specific mAbs, sCD4 was
shown to modestly enhance the infectivity of HIV-1
at suboptimal concentrations in CD4-/CCR5+ cells
[30], which is more prominent in some simian immuno-
deficiency virus (SIV) and SIV-related HIV-2 strains
[14,42-45]. This phenomenon was explained by the hy-
pothesis that sCD4 can efficiently replace cell-surface
CD4 to drive virus infection in CD4-negative and CCR5-
positive cells [30]. In the present study, we found that
the soluble D1D2 molecule could enhance infectivity of
a CCR5-using HIV-1 strain Bal in Cf2Th-CCR5 (CD4-/
CCR5+) cells at the concentration from 5 to 200 nM,
while 2DLT and T1144 exhibited no enhancement of
HIV-1 infection at the same concentration range. This
suggests that unlike the soluble D1D2 protein, the D1D2
domains in 2DLT may not be able to replace CD4 onTable 3 Effect of pre-incubation of the virus with




IC50 ( nM ) for inhibiting HIV-1 Bal infection
D1D2 2DLT T20 T1144
0 137.10 ± 6.66 11.85 ± 2.23 32.35 ± 6.86 2.92 ± 1.01
15 129.25 ± 7.22 7.52 ± 3.65 27.35 ± 3.26 2.71 ± 0.98
60 103.27 ± 6.26 3.22 ± 1.20 20.13 ± 4.21 2.61 ± 0.58
240 86.69 ± 6.13 2.38 ± 0.59 20.51 ± 3.22 2.22 ± 0.82
* Data are representative of two similar experiments tested in triplicate
(mean ± SD).cell surface to drive HIV-1 infection in the CD4-/CCR5+
cells or the rapid decay of the gp41 fusion-intermediate
mediated by 2DLT results in the abolishment of the
potential enhancement of HIV-1 infection.
We have demonstrated that like the isolated T1144
peptide, the T1144 domain in 2DLT could also effect-
ively inhibit HIV-1 infection and HIV-1-mediated cell-
cell fusion (Figure 6 and Table 2). The dual functions of
2DLT make it superior to the other kind of inactivators
(such as N9 or C31G) since if the HIV-1 virions are not
completely inactivated, 2DLT is able to block the viral
fusion and entry with its T1144 domain.
We have not tested the ability of 2DLT to induce
drug-resistant mutations in HIV-1 variants because it
will be difficult to interpret the results from the HIV
entry inhibitor-induced mutation studies. For example,
people may generally believe that sCD4 should induce
drug-resistant mutations in the CD4-binding site in viral
gp120. However, the mutation sites in the sCD4-
resistant HIV-1 variants were mainly located in the V1,
V2, and V3 loops in gp120 and the NHR region in gp41
[46]. Similarly, the mutation sites in the HIV-1 variants
resistant to T2635, an analogous peptide of T1144, were
not located in the hydrophobic pocket of the gp41 NHR
domain, which is the main target site of T2635, T1144
and other C-peptides with the pocket-binding domain,
but rather in other regions in gp120 and gp41 [47]. This
could be possibly explained by the fact that both the
CD4 binding site in gp120 and the hydrophobic pocket
in gp41 are highly conserved, and the viruses with muta-
tions at these sites may not survive due to the loss of
the critical viral functions. Therefore, both D1D2 and
T1144 may possess high genetic barrier to resistance.
We expect that 2DLT may have a higher genetic barrier
to resistance than D1D2 and T1144 when each of them
is used alone since 2DLT, like the combination of D1D2
and T1144, is able to simultaneously interact with two

































Figure 7 The putative mechanisms of action of 2DLT to inactivate virions and to inhibit viral fusion and entry. 2DLT binds to gp120 via
its D1D2 domain and induces the exposure of the grooves of the gp41 trimer, which subsequently binds the T1144 domain in 2DLT, leading to
irreversible inactivation of HIV-1 (model a). Like T1144, 2DLT may also directly bind to gp41 NHR via the T1144 domain to inhibit HIV-1 fusion
with the target cell (model b).
Lu et al. Retrovirology 2012, 9:104 Page 10 of 14
http://www.retrovirology.com/content/9/1/104Conclusions
We have designed and engineered a bivalent protein
2DLT, which can speed the T1144 domain-mediated
decay of the gp41 PFI induced by binding of D1D2
domain to gp120, resulting in rapid inactivation of HIV-1
virions. It may also inhibit HIV-1 fusion and entry
through its T1144 domain in case when the HIV-1 virion
escapes from 2DLT-mediated inactivation. Both of its
binding sites in gp120 and gp41 are highly conserved, and
it can actively attack the virus in the absence of host cells,
making it a promising candidate for further development
as a therapeutic for the treatment of HIV/AIDS or as a




CHO cells stably transfected with either the HIV-1HXB2
Env-expressing vector pEE14 (CHO-WT) or control
pEE14 vector (CHO-EE) were cultured in Glutamine-
deficient minimal essential medium (GMEM-S) contain-
ing 400 μM Methionine sulfoximine (Sigma, St. Louis,
MO). Cf2Th/syn CCR5 cells stably expressing CCR5
receptors were cultured in DMEM complemented
medium with 10% FBS, pen/strep, 500 μg/ml G418,
500 μg/ml zeocin and 3 μg/ml puromycin (Invitrogen,
Carlsbad, CA). MT-2 and TZM-b1 cells, as well as
laboratory-adapted HIV-1 strains IIIB and Bal, and pri-
mary HIV-1 isolates were obtained from the AIDSResearch and Reference Reagent Program of NIH. The
N-peptide N36 (aa 546–581), and C-peptides C34
(aa 628–661), T1144, and T20 (aa 638–673), used in this
study were derived from the NHR and CHR, respect-
ively, of the HIV-1HXB2 gp41 (Figure 1A). These peptides
(> 95% purity) were synthesized by a standard solid-
phase FMOC method using an Applied Biosystems
model 433A peptide synthesizer.
Construction of vectors encoding D1D2 and 2DLT
To create the expression plasmid pD1D2-PDI and
p2DLT-PDI, DNA fragments encoding D1D2 (aa 1–185
of CD4), the 35-mer linker (GGGGS)7, and T1144 were
linked together by three-step overlapping PCR. We














GTAAAGCTTCTATCC-30) DNA fragments were genera-
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pairs. Second, the DNA fragments coding for L35 and
T1144 were linked by overlapping PCR with the primers
FL35 and RT1144. Third, the two DNA fragments
encoding D1D2 and L35-T1144 were linked by overlap-
ping PCR with the DNA fragment D1D2 and the primers
FD1D2his and RT1144. Finally, the amplified DNA frag-
ment coding for 2DLT was digested by BamHI and EcoR I
and inserted into the expression vector pGEX-6p-1 to
generate the p2DLT plasmid. In order to prevent the for-
mation of the inclusion bodies in E. coli, we inserted a
protein disulfide isomerase (PDI) [21,22] DNA sequence
(aa 18–508) with PreScission protease cutting site (called
ppase site) in the N terminus into the EcoR I and Xho I
sites located at the C terminus of His-2DLT gene in
the plasmid p2DLT to extend the GST-his-2DLT read-
ing frame, resulting in the generation of chimeric GST-
his-2DLT-ppase-PDI. This plasmid is called p2DLT-PDI.
The sequences were confirmed by DNA sequencing.
Protein expression and purification
To express D1D2 and 2DLT fusion proteins, Escherichia
coli strain Rosetta 2 (DE3) pLysS (Novagen) was trans-
formed with pD1D2-PDI and p2DLT-PDI, respectively,
cultured at 37°C to OD600 = 0.4, then induced at 16-
22°C for 8–12 h with 0.4 mM IPTG. The cells were
harvested and lysed by sonication in the presence of
protease inhibitor mixture (Roche). After centrifugation,
supernatants containing the fusion protein were collected.
The protein was purified with Glutathione-Sepharose 4B
affinity columns and cleaved with PreScissionTM Protease
(GE Healthcare). These fusion proteins were purified
by His•BindW Purification Kit (Novagen) and fast protein
liquid chromatography (FPLC), and then analyzed by
SDS-PAGE.
SDS-PAGE and Western blot analysis
Purified fusion proteins were analyzed by SDS-PAGE as
previously described [48]. Briefly, D1D2 or 2DLT was
mixed with 4X SDS sample buffer (Novagen, Gibbstown,
NJ) and boiled for 5 minutes or kept at room
temperature (RT) before loading onto a 10-20% Tricine-
Glycine gel (Invitrogen, Carlsbad, CA). The electro-
phoresis was conducted in SDS-PAGE running buffer
with 125 V constant voltage at 4°C. In Western blot, the
anti-human CD4 and anti-T1144 polyclonal antibodies
were used.
Enzyme-linked immunosorbent assay (ELISA)
D1D2 and 2DLT fusion proteins were characterized by
ELISA as previously described [49]. Briefly, they were
coated onto a 96-well polystyrene plate (Costar, Corning
Inc., Corning, NY) (10 μg/ml in 0.1 M Tris–HCl,
pH 8.8), which was blocked with 2% non-fat milk inPBS. The polyclonal antibodies against CD4, conformation-
dependent monoclonal antibody against CD4 (Sim.4) and
anti-T1144 polyclonal antibody, respectively, were added
to the plate. After incubation at 37°C for 60 min, horse-
radish peroxidase (HRP)-labeled antibodies (ZYMED
Laboratories, S. San Francisco, CA) and the substrate
TMB (Sigma) were added, sequentially. The binding
of D1D2 and 2DLT to gp120 or gp41 NHR, and their
inhibitory activity on gp41 6-HB formation were deter-
mined by ELISA as previously described [50].
Flow cytometry
The binding of D1D2 and 2DLT to gp120/gp41
expressed on the cell surface was detected by flow cyto-
metry as previously described [49,51]. Briefly, the cul-
tured CHO-WT (with Env) and CHO-EE (with no Env)
cells were detached from plate and washed with wash
buffer (PBS containing 5% GBS) three times and incu-
bated with the testing protein for 1 h at 4°C. After three
washes, anti-CD4 or anti-T1144 polyclonal antibody was
added for 1 h at 4°C. After three washes, FITC-
conjugated anti-rabbit or mouse antibody was added
and incubated for 1 h at 4°C. After three washes, the
cells were examined by flow cytometry and the fluores-
cence intensity was recorded by FACSCalibur (Becton
Dickinson).
Surface plasmon resonance (SPR) assay
The binding affinity of D1D2 and 2DLT to gp120 was
measured by SPR using the BIAcore3000 system (Phar-
macia, Piscataway, NJ), following the Manual of the Bio-
molecular Interaction Analysis (BIA) Technology as
described previously [52]. Briefly, gp120 (100 μg/ml) was
immobilized onto the CM3 sensor chip by amine coup-
ling, and the unreacted sites were blocked with ethanola-
mine. The dissociation reaction was done by washing
with running buffer (10 mM HEPES pH7.4 containing
0.15 M NaCl, 3.4 mM EDTA and 0.005% v/v surfactant)
for at least 2 min.
Fluorescence native polyacrylamide gel electrophoresis
(FN-PAGE)
FN-PAGE for detecting 6-HB formation as described be-
fore [27]. Briefly, a testing peptide or protein (100 μM)
was pre-incubated with N36 (100 μM) at 37°C for
30 min, followed by addition of C34-FAM (100 μM) at
37°C for 30 minutes. The mixtures were added into
Tris-glycine native sample buffer (Invitrogen, Carlsbad,
CA). The samples (20 μl) were then loaded onto Tris-
glycine gels (18%; Invitrogen, Carlsbad, CA), which were
run under 120 V constant voltage at room tempera-
ture for 1 h. The gels were stained and visualized with
the FluorChem 8800 Imaging System (Alpha Innotech
Corp., San Leandro, CA) using a transillumination UV
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then with Coomassie Blue.
Inhibition of HIV-1 infection
Inhibitory activities of D1D2 and 2DLT on HIV-1 infec-
tion were determined as previously described [53,54].
For inhibition of HIV-1 IIIB (subtype B, X4) infection,
100 TCID50 of the virus was added to 1 × 10
4/ml MT-2
cells in RPMI medium 1640 containing 10% FBS in
the presence or absence of the test peptide or protein
overnight. The culture supernatants were removed, and
fresh media were added. On the fourth day post-infec-
tion, culture supernatants were collected for detection
of p24 antigen by ELISA. For inhibition of infection
by the HIV-1 strain Bal (subtype B, R5), TZM-bl cells
(1 × 105/ml) were pre-cultured overnight and infected
with Bal at 100 TCID50 in the presence or absence of
the test peptide or protein overnight. The cells were har-
vested and lysed on the fourth day post-infection with
lysing reagent. The luciferase activity was analyzed using
a luciferase kit (Promega, Madison, WI) and a lumin-
ometer (Ultra 386, Tecan, Durham, NC) according to
the manufacturer’s instructions. For testing the effect of
pre-incubation times on the inhibitory activity of 2DLT,
the TZM-b1 assay was performed after pre-incubation
of the HIV-1 Bal virus with the inhibitors for 0, 15, 60
and 240 min. For inhibition of primary HIV-1 isolate in-
fection, peripheral blood mononuclear cells (PBMCs)
were isolated from the blood of healthy donors. The
PHA-stimulated cells were infected with a primary HIV-
1 isolate at a multiplicity of infection (MOI) of 0.01 in
the absence or presence of peptide or protein at graded
concentrations. The supernatants were collected on
the 7th day post-infection and tested for p24 antigen
by ELISA as previously described [54,55]. The per-
cent inhibition of p24 production or luciferase activity
was calculated.
Inactivation of HIV-1 virions
The virus inactivation by D1D2 and 2DLT was deter-
mined as previously described [25,56,57]. Briefly, 100 μl
of the protein or peptide at graded concentration were
added to 100 μl of an HIV-1 strain (200 TCID50/ml), fol-
lowed by incubation at 4°C for 1 h. Then, PEG-6000 was
added to the treated virus at final concentration of 3%,
4°C for 1 h. The mixture was centrifuged on a microfuge
at 15,000 rpm for 30 min. The supernatants were
removed and the pellet was washed with 3% PEG in PBS
containing 10 mg/ml BSA. The viral pellet was then
resuspended in 100 μl of PBS, before addition of 100 μl
MT-2 or TZM-bl cells (1 × 105/ml). After cultur at 37°C
for 3 days, p24 production in MT-2 cell culture or luci-
ferase activity in TZM-bl cell culture was tested as previ-
ously described [58-60].Cell-based ELISA
To measure the effects of D1D2 and 2DLT on induction
of short-lived PFI of HIV-1 Env, we used a cell-based
ELISA as previously described [14]. Briefly, CHO-WT
cells steadily expressing HIV-1 Env were seeded in 96-
well plates (5 × 104/well). Cells were then harvested and
washed twice with blocking buffer (35 mg/ml BSA,
10 mg/ml non-fat dry milk, 1.8 mM CaCl2, 1 mM
MgCl2, 25 mM Tris, pH 7.5 and 140 mM NaCl). For
pulse activation experiments, the cells were incubated
with D1D2 (2.5 μM) or 2DLT (2.5 μM) suspended in
blocking buffer for three minutes, washed three times
with blocking buffer and incubated with the C34-biotin
(2 μM). To study the temperature dependence of NHR
groove exposure, the D1D2- or 2DLT-pulsed cells were
incubated at the requisite temperature for different
lengths of time. The cells were subsequently returned to
room temperature for incubation with C34-biotin. Cells
were then washed four times with blocking buffer
and four times with washing buffer (140 mM NaCl,
1.8 mM CaCl2, 1 mM MgCl2 and 20 mM Tris, pH 7.5).
A horseradish peroxidase-conjugated streptavidin (ZYMED
Laboratories, S. San Francisco, CA) was then incubated
with the samples for 45 minutes at room temperature.
Cells were washed 5 times with blocking buffer and
5 times with washing buffer. HRP enzyme activity was
determined after the addition of 33 μl per well of a 1:1
mixture of Western Lightning oxidizing and luminal
reagents (Perkin Elmer Life Sciences) supplemented with
150 mM NaCl. Light emission was measured.HIV-1 infectivity in CD4-/CCR5+ cells treated by D1D2
or 2DLT
The effects of D1D2 and 2DLT on HIV-1 infection of
CD4-/CCR5+ target cells were evaluated as previously
described [14]. Briefly, HIV-1 Bal (100 TCID50/well was
cultured with Cf2Th-CCR5 cells (1 × 106 cells per well)
at room temperature for 1 h, then was resuspended,
followed by addition of D1D2 or 2DLT at different con-
centrations. After a short centrifugation, the mixture
was incubated for 8–12 h at room temperature. The
viral infectivity was measured three days later.
Inhibition of HIV-1-mediated cell-cell fusion
HIV-1 mediated cell-cell fusion was measured with a
dye transfer assay as previously described [27,29]. In
brief, the HIV-1IIIB chronically infected H9 (H9/HIV-1IIIB)
cells were labeled with Calcein-Am (Molecular Probes,
Inc., Eugene, OR). After washes, the fluorescence-labeled
H9/HIV-1IIIB cells were incubated with MT-2 cells at
37°C for 2 h in the absence or presence of an inhibitor
at a graded concentration. The percentage of fused cells
was counted under a fluorescence microscope (Zeiss,
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each drug was calculated with the Calcusyn software
program [27,29].
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